Evaluation of Bone Metabolism Biomarkers in Hemodialysis Chronic Kidney Disease

Metabolic bone disease (MBD) is a common complication of chronic kidney disease (CKD) and is a part of a broad spectrum of disorders of mineral metabolism that occur in this clinical setting and result in both skeletal and extraskletal consequences. This study was a cross sectional which conducted in Dialysis Unit in Tikrit Teaching Hospital in Tikrit city. The study started from January 2018 to August 2018 on study population age ranged from (18–68) years old The total of 60 subjects were separated to two groups as following: Control: This group consist of 30 healthy individuals (15 females and 15 males), and Hemodialysis (HD) (CKD) patients: This group consist of CKD 30 patients (15 females and 15 males). The results referred to the increased levels of Transforming growth factor-β (TGF-β), Osteoprogestrin (OPG), Sclerostin (SOST), Osteocalcin (OC) and C-reactive protein (CRP) in CKD with HD with highly significant differences (P≤0.01) when compared with control group. The bone metabolism biomarkers are increased in HD CKD patients who complicated to MBD.